Primary endpoint analysis from a response adaptive phase II clinical trial of carfilzomib, lenalidomide, dexamethasone plus daratumumab (KRd-Dara) in patients with newly diagnosed multiple myeloma (NDMM) Meeting Abstract
| Authors: | Bhutani, M.; Robinson, M.; Atrash, S.; Paul, B.; Pineda-Roman, M.; Foureau, D.; Varga, C.; Friend, R.; Begic, X.; Norek, S.; Drennan, T.; Anderson, M. B.; Symanowski, J.; Voorhees, P. M.; Usmani, S. Z. |
| Abstract Title: | Primary endpoint analysis from a response adaptive phase II clinical trial of carfilzomib, lenalidomide, dexamethasone plus daratumumab (KRd-Dara) in patients with newly diagnosed multiple myeloma (NDMM) |
| Meeting Title: | 65th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 142 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2023 Dec 9-12 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2023-11-02 |
| Start Page: | 3380 |
| Language: | English |
| ACCESSION: | WOS:001159740303243 |
| DOI: | 10.1182/blood-2023-174972 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract -- Source: Wos |
